Ensysce Biosciences, Inc. (ENSC) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 2 Buy.
Analysts estimate Earnings Per Share (EPS) of $-8.34 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-4.57 vs est $-8.34 (beat +45.2%). 2025: actual $-3.98 vs est $-4.73 (beat +15.9%). Analyst accuracy: 49%.
ENSC Analyst Ratings
Buy
Based on 2 analysts giving stock ratings to Ensysce Biosciences, Inc. in the past 3 months
EPS Estimates — ENSC
49%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$4.57
vs Est –$8.34
▲ 82.4% off
2025
Actual –$3.98
vs Est –$4.73
▲ 18.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ENSC
80%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual $0.005B
vs Est $0.004B
▲ 20.3% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
